Joseph Charalel

Vice President

2024 - Current

• Lead diligence / source new investment deals • Support portfolio companies at the board level • Manage positions in public biotech portfolio companies

Senior Associate

2022 - 2023

Board Observer

2023

Board Observer

2022

Board Observer

2022

PhD Candidate in Genetics

2013

• Perform research in the laboratory of Dr. Christina Curtis on the genetic and epigenetic basis of drug resistance in HER2+ breast cancers via multi-omic profiling. Focus on using genome-wide sequencing assays and machine learning to understand drug response using in vitro model systems and patient data. (2015-Present) • Researcher in the laboratory of Dr. Atul Butte (now at UCSF). Worked on in silico characterization of cancer cell lines as tumor models using publicly available omics data. (2014-2015)

Guest Lecturer

2023

Guest lecturer on valuation methodology - INDE 209: Analysis of Public Companies in the Life Sciences

Board Observer

2023 - 2024

Manager

2018 - 2021

Focused on healthcare and investment due diligence

General Partner

2017 - 2018

• Equity partner and manager in small-cap biotech fund led by Stanford trainees

Intern

2017 - 2018

• Performed due diligence to identify potential new investment opportunities and develop comprehensive thesis for a particular therapeutic area • Contributed to company analysis efforts which led to investment decisions • Led key opinion leader calls, analyzed primary research literature, analyst reports to develop comprehensive commercial and scientific view of the key opportunities in the space • Synthesized and presented findings to Longitude leadership